BLEPHAMIDE by AbbVie is clinical pharmacology corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Approved for inflammatory conditions of the palpebral, bulbar conjunctiva, cornea and 7 more indications. First approved in 1961.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
BLEPHAMIDE is a fixed-combination ophthalmic suspension containing a corticosteroid and sulfacetamide sodium antibiotic for topical ocular use. It treats inflammatory conditions of the eye including conjunctivitis, uveitis, and corneal injury while providing bacteriostatic coverage against common ocular pathogens. The corticosteroid suppresses inflammation and edema while sulfacetamide restricts bacterial folic acid synthesis.
Product approaching loss of exclusivity with limited commercial runway; teams likely focused on lifecycle management and generic transition planning.
CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antibacterial drug may be used when this inhibition is considered…
Worked on BLEPHAMIDE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on BLEPHAMIDE offers limited career growth given its LOE-approaching lifecycle stage and zero linked job openings. Career value lies in managing portfolio wind-down, generic transition, and operational efficiency rather than growth and expansion.